Sanofi SA / Ablynx NV

Immune-Mediated Inflammatory Diseases (multiple)

Disease Overview

Immune-mediated inflammatory diseases (IMIDs) span rheumatoid arthritis, psoriasis, atopic dermatitis, IBD and others — chronic conditions where dysregulated cytokine signaling drives tissue damage. Treatment is dominated by injectable monoclonal antibodies and oral JAK inhibitors. The collaboration covered up to eight Nanobody product candidates against undisclosed targets and indications, so this enrichment treats the field at a class level rather than a single indication.

Competitive Landscape

At deal time the IMID market was dominated by Humira (adalimumab, AbbVie), Stelara (ustekinumab, Janssen), Cosentyx (secukinumab, Novartis), Dupixent (dupilumab, Sanofi/Regeneron — launched March 2017) and rapidly expanding JAK class led by Pfizer's Xeljanz. Sanofi was simultaneously launching Dupixent in atopic dermatitis and Kevzara (sarilumab) in RA, so the Ablynx tie-up gave Sanofi a way to extend its IMID franchise with multi-specific Nanobodies — single-domain antibody fragments that can be engineered to hit multiple targets in one molecule, potentially leapfrogging the limits of single-cytokine biologics. Industry coverage flagged the asymmetric structure: only EUR 23M (~$26M) upfront against up to EUR 2.4B in biobucks, much smaller than Ablynx's 2013 AbbVie deal which had $175M upfront for a Phase 3-ready Nanobody. The lower upfront reflected earlier-stage discovery scope. The collaboration was effectively superseded six months later when Sanofi acquired Ablynx outright for $4.8B in January 2018, validating the platform thesis.